Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

0(0%)

Results Posted

50%(1 trials)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

3(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(1)

Detailed Status

Completed2

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 1

Trials by Phase

Phase 13 (100.0%)

Trials by Status

completed267%

withdrawn133%

Recent Activity

0 active trials

Showing 3 of 3

withdrawnphase_1

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

NCT06284460

completedphase_1

Study of ASTX029 in Subjects With Advanced Solid Tumors

NCT03520075

completedphase_1

A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029

NCT04466514

Clinical Trials (3)

Showing 3 of 3 trials

NCT06284460Phase 1

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Withdrawn

NCT03520075Phase 1

Study of ASTX029 in Subjects With Advanced Solid Tumors

Completed

NCT04466514Phase 1

A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3